<DOC>
	<DOCNO>NCT00229697</DOCNO>
	<brief_summary>This study carry see ZD1839 effective treating metastatic breast cancer combination Nolvadex , , compare Nolvadex alone .</brief_summary>
	<brief_title>Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Histologically confirm metastatic adenocarcinoma breast ( seeTNM stag Appendix I ) ER and/or PR positive determine local laboratory investigator site ( central verification ER status perform patient start treatment A tissue block either metastatic primary tumor site require . WHO performance status ( PS ) 02 Patients must pregnant breastfeeding . A negative pregnancy test require within 7 day prior randomization pre perimenopausal . Postmenopausal patient define : natural menopause last menses &gt; 1 year ago , radiation induce oophorectomy last menses &gt; 1 year ago , chemotherapy induce menopause 1 year interval since last menses , serum FSH LH plasma estradiol level postmenopausal range institution . bilateral oophorectomy Patients hormone replacement therapy receive prior chemotherapy metastatic disease . Patients previously treat Tyrosine Kinase inhibitor evidence active interstitial lung disease eligible . Treatment LHRH analog . Laboratory value follow Bilirubin &gt; 1.5 time upper limit normal ULN , alanine amino transferase ( ALT ) aspartate amino transferase ( AST ) &gt; 2.5 time ULN demonstrable liver metastasis , &gt; 5 time ULN presence liver metastases Bone marrow function : WBC &lt; 1500 mm3</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
</DOC>